Elite Pharmaceuticals, Inc. (ELTP)

OTCMKTS: ELTP · Delayed Price · USD
0.123
-0.004 (-3.14%)
Apr 23, 2024, 3:26 PM EDT - Market closed
Market Cap 125.39M
Revenue (ttm) 47.32M
Net Income (ttm) 15.55M
Shares Out 1.02B
EPS (ttm) 0.02
PE Ratio 8.16
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 797,573
Open 0.128
Previous Close 0.127
Day's Range 0.121 - 0.128
52-Week Range 0.030 - 0.210
Beta -0.14
Analysts n/a
Price Target n/a
Earnings Date Aug 14, 2023

About ELTP

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P ... [Read more]

Sector Healthcare
IPO Date Jul 23, 1998
Employees 53
Stock Exchange OTCMKTS
Ticker Symbol ELTP
Full Company Profile

Financial Performance

In 2022, ELTP's revenue was $34.16 billion, an increase of 105767.55% compared to the previous year's $32.26 million. Earnings were $4.41 billion, an increase of 49459.23%.

Financial Statements

News

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information

Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pha...

2 months ago - Accesswire

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024

Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024 NORTHVALE, NJ / ACCESSWIRE / February 8, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the ...

2 months ago - Accesswire

Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant

NORTHVALE, NJ / ACCESSWIRE / December 26, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and di...

4 months ago - Accesswire

Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC

NORTHVALE, NJ / ACCESSWIRE / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announ...

4 months ago - Accesswire

Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information

Conference Call Scheduled for Wednesday, November 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty p...

5 months ago - Accesswire

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023

Financials for Second Quarter Fiscal Year 2024 Ended September 30, 2023 will be released on November 14, 2023 NORTHVALE, NJ / ACCESSWIRE / November 10, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or t...

5 months ago - Accesswire

Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product

NORTHVALE, NJ / ACCESSWIRE / September 25, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and di...

7 months ago - Accesswire

Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer

NORTHVALE, NJ / ACCESSWIRE / September 7, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic prod...

8 months ago - Accesswire

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

NORTHVALE, NJ / ACCESSWIRE / August 28, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distr...

8 months ago - Accesswire

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023

Financials for First Quarter Fiscal Year 2024 Ended June 30, 2023 will be released on August 14, 2023 NORTHVALE, NJ / ACCESSWIRE / August 9, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company...

9 months ago - Accesswire

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information

Conference Call Scheduled for Friday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutic...

10 months ago - Accesswire

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023

Financials for Fiscal Year 2023 Ended March 31, 2023 will be released on June 29, 2023 NORTHVALE, NJ / ACCESSWIRE / June 22, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP),...

10 months ago - Accesswire

Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer

NORTHVALE, NJ / ACCESSWIRE / May 3, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, ...

1 year ago - Accesswire

Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product

NORTHVALE, NJ / ACCESSWIRE / April 20, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced...

1 year ago - Accesswire

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information

Conference Call Scheduled for Wednesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty p...

1 year ago - Accesswire

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2023 Financial Results on February 15, 2023

Financials for Third Quarter Fiscal Year 2023 Ended December 31, 2022 will be released on February 14, 2023 NORTHVALE, NJ / ACCESSWIRE / February 8, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the ...

1 year ago - Accesswire

Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist

NORTHVALE, NJ / ACCESSWIRE / December 22, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announ...

1 year ago - Accesswire

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information

Conference Call Scheduled for Tuesday, November 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 15, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty phar...

1 year ago - Accesswire

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information

Conference Call Scheduled for Tuesday, August 16 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / August 15, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmace...

1 year ago - Accesswire

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2023 Financial Results on August 16, 2022

Financials for First Quarter Fiscal Year 2023 Ended June 30, 2022 will be released on August 15, 2022 NORTHVALE, NJ / ACCESSWIRE / August 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Compan...

1 year ago - Accesswire

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information

Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceut...

1 year ago - Accesswire

Elite Pharmaceuticals Receives FDA Approval for Generic Sabril(R)

NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced ...

1 year ago - Accesswire

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2022 Financial Results on June 30, 2022

Financials for Fiscal Year 2022 Ended March 31, 2022 will be released on June 29, 2022 NORTHVALE, NJ / ACCESSWIRE / June 23, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP),...

1 year ago - Accesswire

Elite Pharmaceuticals, Inc. Appoints Robert Chen as Chief Financial Officer

NORTHVALE, NJ / ACCESSWIRE / May 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products,...

2 years ago - Accesswire

Elite Pharmaceuticals and Praxgen Pharmaceuticals Receive FDA Approval for Generic Doxycycline

NORTHVALE, NJ / ACCESSWIRE / April 4, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced ...

2 years ago - Accesswire